Aptimmune Biologics announces the addition of two members to the company’s management team to start the new year. Heather Bessoff, DVM, has joined the company as chief executive officer. In her new role, Bessoff will oversee all aspects of the company’s operations, including commercial vaccine development, research, sales and marketing for the company’s vaccine products made with Barricade formulation technology.

Previously, Bessoff was a business management consultant for startup biotechnology companies, private equity and venture capital firms in the animal health industry. In addition, she held similar business development positions at EpiBome Inc., Elanco Animal Health and Pfizer, and has nearly 30 years of clinical, research and development and business management experience in all facets of animal health. Bessoff received her DVM degree from the University of Wisconsin and bachelor of science in animal science/pre-vet from the University of Connecticut.

In addition, Perry Harms, DVM, has been named technical consultant for Aptimmune. A swine consultant with more than 25 years of experience in the industry, Harms will consult with the research and development team and help support field application and sales. His past positions include veterinarian and general manager for Smithfield Foods and diagnostician at Texas A&M University and Iowa State University veterinary diagnostic laboratories. Harms received his DVM, masters of science in Veterinary Pathology, and bachelor of science in Animal Science from Iowa State University.

“We are extremely pleased to have Dr. Bessoff and Dr. Harms joining the Aptimmune organization,” says Robert Nordgren, chairman of the board for the company. “Both bring tremendous swine health and production knowledge and experience that will benefit Aptimmune and our customers as we continue to develop and market solutions that improve swine production.”

For more information about Aptimmune Biologics, its Barricade vaccine products, contact the corporate office at (317) 690-7097 or visit Aptimmune.com.

Source: Aptimmune Biologics, which is solely responsible for the information provided and is wholly owned by the source. Informa Business Media and all its subsidiaries are not responsible for any of the content contained in this information asset.